Your Previous Searches:
Recently Visited Pages:
BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercialising innovative products for the prevention and treatment of infectious diseases and other illnesses. It is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases such as COVID-19, asthma and psoriasis.
In this interview, Dr Tamar Ben-Yedidia, BiondVax’s chief science officer, discusses the company’s current strategy, the progress made with its NanoAb pipeline and forthcoming milestones.
Get access to the very latest content matched to your personal investment style.